Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04477629 · ClinicalTrials.gov registry record · Phase 2
Belatacept in De Novo Heart Transplantation
A Phase 2 study of Heart Transplantation, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 2
- Study locations
NCT04477629 is a Phase 2 study of Heart Transplantation that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 12 participants, below the 589-participant average among 4 other Heart Transplantation trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT04477629, a Phase 2 study of Heart Transplantation, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine if Belatacept is safe to give to adult heart transplant recipients. Belatacept (NULOJIX) is an anti-rejection medication that is available through a prescription from a doctor. In this research study, belatacept is being used in an investigational manner (not for the purpose that it is approved for).
Conditions Studied
Interventions
- DRUG Corticosteroid
- DRUG Mycophenolate Mofetil
- DRUG Tacrolimus
- DRUG Belatacept
Study Locations (2)
New York
- NYU Langone Health - New York
- Columbia University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2020-08-06 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04477629
The ClinicalTrials.gov registry entry for NCT04477629 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 589-participant average among 4 other Heart Transplantation trials with a reported enrollment target (98% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heart Transplantation appearing as the primary indexed condition, and to 4 interventions - of which Corticosteroid is the first listed.
NCT04477629 reports 2 study locations spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04477629 about?
NCT04477629 is a clinical study titled "Belatacept in De Novo Heart Transplantation". The purpose of this study is to determine if Belatacept is safe to give to adult heart transplant recipients. Belatacept (NULOJIX) is an anti-rejection medication that is available through a prescription from a doctor. In this research study, belatacept is being used in an investigational manner (no...
What is the current status of trial NCT04477629?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2020-08-06. Estimated completion is 2026-09.
What conditions does trial NCT04477629 study?
This clinical trial studies the following conditions: Heart Transplantation.
What interventions are being tested in trial NCT04477629?
The interventions under investigation include: Corticosteroid (DRUG), Mycophenolate Mofetil (DRUG), Tacrolimus (DRUG), Belatacept (DRUG).
Who is sponsoring clinical trial NCT04477629?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04477629 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Transplantation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Magnetocardiography as a Non-Invasive Tool for Detecting Tissue Rejection in Heart Transplant Patients
COMPLETED · Phase 3
-
A Study of Safety, Tolerability & Efficacy of Certican in de Novo Heart Transplant (Tx) Patients
COMPLETED · Phase 3
-
Trajectories of Cardiac Allograft Vasculopathy After Heart Transplantation
COMPLETED
-
Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.